RSPH ETF Analysis: SP500 Equal Weight Health | NYSE

Health | NYSE, USA | Market Cap: 730m USD | 12M Return: 16% | Charts, Fundamentals & Technical Analysis

Pharmaceuticals, Biotechnology, Medical Equipment, Health Services
Total Rating 51
Safety 68
Buy Signal -0.02
Health
Category Rotation: +6.8
TER: 0.40%
AUM: 730M
Avg Turnover: 3.98M
Risk 3d forecast
Volatility16.8%
VaR 5th Pctl2.98%
VaR vs Median-1.43%
Reward TTM
Sharpe Ratio0.74
Rel. Str. IBD53
Rel. Str. Peer Group20.6
Character TTM
Beta0.475
Beta Downside0.485
Hurst Exponent0.501
Drawdowns 3y
Max DD17.13%
CAGR/Max DD0.26
CAGR/Mean DD0.80

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Seasonality 10.5 years of data

Jan +1.8% 30
Feb -2.7% 17
Mar -1.2% 12
Apr -0.5% 16
May +0.2% 23
Jun +1.9% 29
Jul +3.0% 10
Aug -0.3% 19
Sep -2.4% 25
Oct -0.7% 5
Nov +5.4% 55
Dec -1.0% 8

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: RSPH SP500 Equal Weight Health

The Invesco S&P 500 Equal Weight Health Care ETF (RSPH) is a passively managed fund that seeks to track an underlying index by investing at least 90% of its total assets in the indexs component securities. The index itself is built from all companies within the S&P 500 Index that are classified under the health care sector according to the Global Industry Classification Standard (GICS), a sector taxonomy jointly maintained by S&P Dow Jones Indices and MSCI.

Unlike market capitalization-weighted approaches, the funds equal weight methodology assigns each constituent a roughly identical portfolio weight at each rebalance, giving smaller health care companies the same influence on performance as the largest sector names. The GICS health care sector broadly spans four industry groups: pharmaceuticals, biotechnology & life sciences, health care equipment & services, and health care providers, though the funds holdings are restricted to those firms also included in the S&P 500.

Headlines to Watch Out For
  • Drug pricing reforms pressure pharma margins across equal-weight holdings
  • FDA approval pipeline drives biotech valuations in portfolio
  • Interest rate cuts lift small-cap biotech weighting impact
What is the price of RSPH shares?

As of July 24, 2026, the stock is trading at USD 33.61 with a total of 158,577 shares traded. Over the past week, the price has changed by -2.10%, over one month by +5.96%, over three months by +9.45% and over the past year by +15.98%.

Current recommended Stop Loss: 32.80 (which is 2.4% or 1.6 ATR below the current price).

Is RSPH a buy, sell or hold?

SP500 Equal Weight Health has no consensus analysts rating.